(a) the promising results found in psychedelic research so far may not replicate, and
(b) even if psychedelics are effective in certain settings, US healthcare infrastructure isn’t configured in a way that will promote those settings
(a) seems to be an argument for doing confirmatory research of the initial results (more discussion of that in this thread).
(b) seems like a valid concern (and is currently a live debate amongst psychedelic advocates).
Psychedelic therapy involves both a psychotherapeutic component & a pharmacological component (and a much bigger one than just “here’s a prescription for some pills, take one pill a day”), so it sits at the intersection of our pharmacology institutions and our psychology institutions.
I think meditation retreat centers & psychotherapy clinics are interesting comparables for how psychedelic therapy could be structured as it enters the US mainstream.
I read Scott as mainly arguing that:
(a) the promising results found in psychedelic research so far may not replicate, and
(b) even if psychedelics are effective in certain settings, US healthcare infrastructure isn’t configured in a way that will promote those settings
(a) seems to be an argument for doing confirmatory research of the initial results (more discussion of that in this thread).
(b) seems like a valid concern (and is currently a live debate amongst psychedelic advocates).
Psychedelic therapy involves both a psychotherapeutic component & a pharmacological component (and a much bigger one than just “here’s a prescription for some pills, take one pill a day”), so it sits at the intersection of our pharmacology institutions and our psychology institutions.
I think meditation retreat centers & psychotherapy clinics are interesting comparables for how psychedelic therapy could be structured as it enters the US mainstream.